Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Twists and turns to translating 4-1BB cancer immunotherapy.

Sanmamed MF., Etxeberría I., Otano I., Melero I.

Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus et al, this issue).

More information Original publication

DOI

10.1126/scitranslmed.aax4738

Type

Journal article

Publication Date

2019-06-01T00:00:00+00:00

Volume

11

Addresses

C, e, n, t, r, o, , d, e, , I, n, v, e, s, t, i, g, a, c, i, ó, n, , M, é, d, i, c, a, , A, p, l, i, c, a, d, a, , (, C, I, M, A, ), ,, , P, a, m, p, l, o, n, a, ,, , S, p, a, i, n, .

Keywords

T-Lymphocytes, Humans, Neoplasms, Antibodies, Bispecific, Immunotherapy